NewEdge Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

NewEdge Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2K	Hold	160	–	–	﹤0.01%	3473
2026 Q1	$12.3K	Hold	160	–	–	﹤0.01%	3346
2025 Q4	$12.6K	Hold	160	–	–	﹤0.01%	3399
2025 Q3	$14.7K	Hold	160	–	–	﹤0.01%	3221
2025 Q2	$10.4K	Buy	160 +85	+113%	+$5.53K	﹤0.01%	3205
2025 Q1	$5.02K	Buy	+75	New	+$4.48K	﹤0.01%	3299

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's ANIP Position: Q2 2026 in Review

NewEdge Advisors held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 160 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3473.

NewEdge Advisors first reported a position in ANIP in Q1 2025 and has held it in 6 quarters since. The position peaked at $14.7K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

NewEdge Advisors held 160 shares of ANI Pharmaceuticals worth $13.2K as of Q2 2026.
NewEdge Advisors left its ANI Pharmaceuticals share count unchanged in Q2 2026.
ANI Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3473 holding.
NewEdge Advisors first reported a position in ANI Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
NewEdge Advisors's ANI Pharmaceuticals position peaked at $14.7K in Q3 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.